10.6084/m9.figshare.5242093.v1 Gevorgyan A. Gevorgyan A. Bregni G. Bregni G. Galli G. Galli G. Zanardi E. Zanardi E. de Braud F. de Braud F. Di Cosimo S. Di Cosimo S. Erratum: HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature Karger Publishers 2017 Neuroendocrine carcinoma Trastuzumab Breast carcinoma 2017-07-25 14:09:06 Dataset https://karger.figshare.com/articles/dataset/Erratum_HER2-Positive_Neuroendocrine_Breast_Cancer_Case_Report_and_Review_of_Literature/5242093 <b><i>Background:</i></b> Neuroendocrine carcinoma is an uncommon histology for breast cancer. <b><i>Case Report:</i></b> Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.